Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavyret in HCV-negative lung transplant recipients from HCV-positive donors
NCT03523871Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- May 2018
- Primary completion
- Sep 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of glecaprevir in hepatitis C (HCV), sponsored by NYU Langone Health. Started May 2018; status: completed.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03523871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523871.